CRISPR-edited B cells treat RSV

INDICATION: Respiratory syncytial virus (RSV)

Mouse studies suggest CRISPR-edited B cells that secrete engineered anti-RSV F protein antibodies could help treat RSV infection. Generation of the cells involves editing primary B cells with a CRISPR system designed to replace an endogenous gene segment with a segment encoding an engineered Synagis palivizumab-derived antibody against RSV F protein. In two mouse models of RSV infection, transfer of CRISPR-edited mouse B cells decreased RSV titers in the lung compared with unmodified mouse B cells. Next steps include safety testing and optimization of the therapy using human B cells...